A5072524955- Cancer Immunotherapy and Biomarkers
- Immune cells in cancer
- Ferroptosis and cancer prognosis
- Glioma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Neuroinflammation and Neurodegeneration Mechanisms
- Cutaneous Melanoma Detection and Management
- Cancer Diagnosis and Treatment
- Polyomavirus and related diseases
- Nonmelanoma Skin Cancer Studies
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- MicroRNA in disease regulation
- Cancer Cells and Metastasis
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Sex and Gender in Healthcare
- Parathyroid Disorders and Treatments
- Eosinophilic Disorders and Syndromes
- Cutaneous lymphoproliferative disorders research
- Dermatologic Treatments and Research
- Lymphoma Diagnosis and Treatment
- melanin and skin pigmentation
- Brain Metastases and Treatment
- Vasculitis and related conditions
University Medical Center Hamburg-Eppendorf
2018-2025
Universität Hamburg
2018-2024
University Cancer Center Hamburg
2021-2024
Purpose: Immunotherapeutic treatment strategies for glioblastoma (GBM) are under investigation in clinical trials. However, our understanding of the immune phenotype GBM-infiltrating T cells (tumor-infiltrating lymphocytes; TILs) and changes during disease progression is limited. Deeper insight urgently needed to therapeutically overcome tumor-induced exhaustion.Experimental Design: We used flow cytometry cytokine assays profile TILs peripheral blood lymphocytes (PBLs) from patients with...
The role of Sentinel Lymph Node Biopsy (SLNB) is pivotal in the contemporary staging cutaneous melanoma. In this review, we examine advanced molecular testing platforms like gene expression profiling (GEP) and immunohistochemistry (IHC) as tools for predicting prognosis sentinel lymph nodes. We compare these innovative approaches with traditional assessments. Additionally, delve into shared genetic protein markers between GEP IHC tests their relevance to melanoma biology, exploring...
Immune checkpoint inhibition has revolutionized melanoma therapy, but many patients show primary or secondary resistance. Biomarkers are, therefore, urgently required to predict response prior the initiation of therapy and monitor disease progression. In this prospective study, we analyzed serum C-C motif chemokine ligand 20 (CCL20) concentration using an enzyme-linked immunosorbent assay. Blood was obtained at baseline before immunotherapy with anti-PD-1 monotherapy Nivolumab Ipilimumab in...
Oral finasteride and topical minoxidil are the current standard of care for male androgenetic alopecia a combination two treatments can be considered greater efficacy. Clinical trials have also yielded promising results, but routine data lacking.
Abstract Background Adjuvant treatment of stage II–IV melanoma with PD‐1‐based immune checkpoint inhibitors (ICI) has improved relapse‐free survival (RFS) and therefore become a standard‐of‐care option. Approximately 25%–30% patients still recur within 1 year. Predictive biomarkers reflecting real‐world data are desired. The predictive relevance tumour tissue PD‐L1 expression in the adjuvant setting remains inconclusive. Objectives This retrospective, observational study was conducted to...
Cutaneous squamous cell carcinoma (CSCC) is the most frequent post-transplant tumour entity resulting from immunosuppression treatment that needed to prevent organ rejection. Solid transplant (SOT) recipients are at higher risk for CSCC and vulnerable aggressive disease or a fatal course. Here, we report on case of post-kidney metastatic CSCC, demonstrating efficacy cemiplimab in achieving complete remission after previous progression under cetuximab treatment. Unfortunately, patient...
Abstract Background The treatment of melanoma has been revolutionized by the use immune checkpoint inhibition (ICI), but many patients do not benefit. Furthermore, immune‐related adverse events may occur during therapy. A predictive biomarker is needed to reliably identify benefitting. In lung, renal cell and bladder cancer early C‐reactive protein (CRP) kinetics were shown be a for ICI. Objective Here, we investigate CRP as ICI in patients. Methods Two independent prospectively collected...
Abstract Background Lung cancer is the leading cause of cancer-related deaths worldwide, with brain metastasis (BM) occurring in 40% advanced non-small cell lung (NSCLC) patients. In 15% these patients, only affected organ (oligo-metastasis), corresponding to improved prognosis compared widespread disease. Thus far, it unknown if metastatic dissemination without systemic metastases a consequence immune system’s ability control tumor outgrowth. Methods Here, we investigated local and...
Non-IgA vasculitis is a rare disease that belongs to the group of small-vessel vasculitides. Due nomenclature and classification changes introduced in 2018, there are few published data under this name. The aim study characterize non-IgA as an independent entity terms demographic, clinical, treatment-related features. A retrospective analysis patients with biopsy-confirmed treated at Department Dermatology University Medical Center Hamburg-Eppendorf between January 1, December 31, 2022, was...
Dear Editors, The anti-PD-L1 immune checkpoint inhibitor (ICI) atezolizumab is a treatment standard for small cell lung cancer (SCLC). Although cutaneous treatment-related adverse events (TRAE) are very common, sclerodermiform eruptions represent rare phenomenon. A 65-year-old female patient with metastatic SCLC presented to our clinic in reduced general condition due following the initiation of palliatively intended combined immune-chemotherapy carboplatin (AUC5 d1), etoposide (100 mg/m2...
<p>Flow-cytometry gating strategy for T-cell differentiation and exhaustion markers.</p>
<p>Supplemental Table 1. Patient characteristics for flow-cytometry analysis. IDH=isocitrate dehydrogenase, MGMT=O6-Methylguanin-DNA-Methyltransferase. Supplemental 2. Matched-paired GBM patient samples TCR repertoire sequencing T=radiotherapy, CT=chemotherapy with temozolomide 3. Antibodies used to polychromatic analysis of T-cells</p>
<p>Additional cytokines determined by multiplex flow-cytometry after PHA stimulation of PBL.</p>
<p>Supplemental data of next-generation T-cell receptor sequencing.</p>
<p>Flow-cytometry gating strategy for T-cell memory/activation and ectoenzymatic exhaustion markers.</p>